1. Home
  2. GMRS vs VALN Comparison

GMRS vs VALN Comparison

Compare GMRS & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GMRS

GMR Solutions Inc. Class A Common Stock

N/A

Current Price

$10.22

Market Cap

551.0M

ML Signal

N/A

Logo Valneva SE

VALN

Valneva SE

N/A

Current Price

$5.25

Market Cap

582.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GMRS
VALN
Founded
2018
2012
Country
United States
France
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
551.0M
582.2M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
GMRS
VALN
Price
$10.22
$5.25
Analyst Decision
Buy
Buy
Analyst Count
8
4
Target Price
★ $18.38
$12.28
AVG Volume (30 Days)
★ 1.1M
9.9K
Earning Date
11-09-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ 0.31
N/A
Revenue
N/A
N/A
Revenue This Year
$4.72
N/A
Revenue Next Year
$5.81
$87.84
P/E Ratio
$32.32
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.00
$4.75
52 Week High
$15.98
$12.18

Technical Indicators

Market Signals
Indicator
GMRS
VALN
Relative Strength Index (RSI) 40.94 37.14
Support Level $9.62 $4.75
Resistance Level $10.93 $5.52
Average True Range (ATR) 0.92 0.21
MACD -0.17 -0.03
Stochastic Oscillator 11.55 0.00

Price Performance

Historical Comparison
GMRS
VALN

About GMRS GMR Solutions Inc. Class A Common Stock

GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: